Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from clinical trials of its weight loss drugs.

Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The news sent the stock sharply higher in premarket trade, before it surrendered those ...

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and competition between pharmaceutical rivals in the GLP-1 weight-loss drug space. Viking reported positive results for its new obesity pill,

By Sriparna Roy and Bhanvi Satija (Reuters) -Viking Therapeutics shares reversed course to fall 8% on Monday as focus shifted to the drug developer's ability to mass produce its oral obesity treatment that was shown to be safe and effective in a small trial.

(Reuters) -Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight with mild side effects in a small trial, data that analysts said compared favorably to some rivals in development.